131 Nanomedicine/Nanotechnology Companies - Worldwide
Search through all Nanomedicine/Nanotechnology companies with powerful filtering options
Company Name | Location | About |
|---|---|---|
Los Angeles, California, United States | Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. | |
Ramona, CA | Abcore, Inc. is a privately held biotechnology company focused on generation of polyclonal, monoclonal, and recombinant antibodies. | |
6190 Agronomy Rd, Vancouver, British Columbia V6T, CA | Acuitas is the premier LNP (lipid nanoparticle) technology provider, enabling our partners to advance new therapeutics to address unmet clinical needs. We have developed a broad IP portfolio focussed on the use of LNP technology for nucleic acid therapeutics. This portfolio primarily encompasses novel compositions of matter but also includes novel uses of nucleic acids therapeutics. Our mission is · To provide our partners with the best LNP delivery technology for nucleic acid therapeutics · To support our partners to rapidly advance new therapeutics to address unmet medical needs · To continually innovate to maintain and strengthen our LNP technological lead Acuitas partners locally and globally with companies, academic institutes and other organizations to improve human health. | |
West Lafayette, Indiana | Adipo Therapeutics, an Indiana biotechnology company, is developing polymer-based, Notch-inhibiting nanoparticles that are injected directly into adipose (fat) tissue to induce browning, or white-to-beige adipocyte transformation. The goal? Reducing weight and restoring metabolic balance for millions of people living with diabetes. | |
Boston, MA | Aera was founded with a vision to unlock the potential of genetic medicines across a broad range of modalities and therapeutic areas. Our protein nanoparticle (PNP) delivery platform leverages the discovery of endogenous, human proteins that can self-assemble to form capsid-like structures and that can package and transfer nucleic acid cargo. This platform has the potential to address many of the limitations of today’s delivery technologies and to enable various genetic medicine modalities. | |
139 Main Street, Cambridge, US | At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes. | |
Cambridge, Massachusetts, United States of America | Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021. | |
Mountain View, California, United States | Applied NanoStructures is a premier supplier of AFM and SPM Probes as well as custom MEMS devices. The AppNano state-of-the-art MEMs foundry is located in the heart of silicon valley. The company was founded by Dr. Ami Chand who has worked in the NanoTechnology area for more than 20 years. | |
Mountain View, California 94043, US | Apurun specializes in tech transfer development and GMP manufacturing services for nanoparticle pharmaceuticals and nanomedicines. Their comprehensive approach enables and supports the development of nanoparticle pharmaceuticals. | |
 | San Diego, California, United States of America | Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). |
Mariakerke, Belgium | Ardena is a pharmaceutical CDMO that guides companies through the drug discovery and development process to help create effective and compliant drug substance and products for clinical trials. Ardena provides you with an integrated service offering including solid state chemistry, API & nanomedicines development and manufacturing, analytical & formulation development, drug product manufacturing, bioanalytical, drug discovery and dossier development services. Headquartered in Ghent, we have facilities in the Netherlands, Belgium, Sweden and Spain, serving a global customer base, ranging from emerging biotech to tier-one pharmaceutical companies. We understand the complex challenges involved in taking a promising molecule from lab to patient. Each project we undertake is preceded by a detailed planning phase to ensure that the right work is carried out at the right time. This staged approach allows you to stagger your investments and mitigate risks during each phase of the project. Our integrated offering is the engine that drives all of our projects. Our multidisciplinary team is keen to streamline your development process. We also make sure that all the work we do for you is compliant with the appropriate regulatory standards as you move along the clinical development path. Our dossier-centric approach is key to help you compile your regulatory dossier in a timely and cost-efficient manner. By preparing your regulatory dossier in parallel with drug development, we ultimately get your drug to patients faster. | |
Boston, Massachusetts, United States | Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients. | |
Basel, Switzerland | ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform, intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization. | |
1235 Radio Rd, Suite 200, Redwood City, California 94065, US | Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology. | |
Cambridge, Massachusetts, United States | Developing seamless neural interfaces. | |
West Palm Beach, Florida, United States | BioCurity Pharmaceuticals Inc. (“BioCurity”), is a biopharmaceutical company with a mission to positively transform radiation therapy for cancer patients, by addressing the global unmet need for an effective treatment to prevent toxicity from radiation therapy (radiation dermatitis). Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity for newly diagnosed patients as well as the millions of cancer patients who continue to receive radiation as a part of their ongoing treatment for cancer. | |
Cardiff, Cardiff | Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity. | |
Ames, Iowa, United States | BioForce Nanosciences, Inc. develops and commercializes nanotech instruments, consumables, and applications for the life sciences. For over a decade we've been a leading provider of consumable support products for atomic force microscopy (AFM). In 2005 we introduced our own flagship instrument platform, the Nano eNabler™ system. The Nano eNabler system is a molecular printer that rapidly and precisely delivers liquids to surfaces such as silicon chips in droplets that are ten billion times smaller than a drop of blood. This unique capability offers researchers in industry and academia a practical solution to problems they encounter when developing ultraminiaturized devices and methods, and creates opportunities for further commercialization of nanotechnology. For example, BioForce’s technology is being used to create biosensors and to study cell biology at the single cell level. Additional applications include printing proteins to guide neural cell growth, printing signaling proteins to study stem cell differentiation, “inking” of micro-stamps for soft lithography, and bio-functionalization of microfluidic devices. | |
Yusong, Taejon-jikhalsi, South Korea | BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization. | |
York, Pennsylvania 17406, US | BioTechnique is a contract manufacturing organization that provides standard and highly-customized cytotoxic and high potency sterile injectable liquid & lyophilized fill-finish services. Our state-of-the-art manufacturing facility is also equipped with a full-scale microbiology lab and offers regulatory affairs, laboratory, and project management support from investigational/clinical all the way through phase IV/commercial. Facility Capabilities: • Sterile injectable manufacturing & packaging for liquid & lyophilized products • Aseptic Vial Filling • Aseptic Lyophilization • Inspection • Formulation • Product Testing • Labeling/Packaging • Stability Storage • Process Design • Full service laboratory • Regulatory affairs support for product filings • Project management Product Capabilities: • Cytotoxics • Highly-Potent Compounds • Monoclonal Antibodies • Antibody Drug Conjugates (ADC) • Suspensions • Inactivated & Attenuated Live Vaccines Filling & Manufacturing Capabilities: • Grade A / ISO 5 Aseptic Filling Suite • 2mL to 100mL vials • 0.2mL to 100mL fill volume • Inline fill volume check weighing • Isolator • 13M2 Lyophilizer • Containment Unloading • Grade A / ISO 5 Capping • Post-Fill / Post-Lyo External Vial Rinse • Single-Use Disposable Manufacturing Train • Vial Inspection & Labeling • ICH Guideline Cold Storage • 2 to 8 ℃ • -20 to -70 ℃ • Stability Chambers & Warehouse Storage • Microbiology & Chemistry Labs | |
Needham, Massachusetts, United States | Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza. | |
 | Salt Lake City, Utah, United States of America | Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapeutics for neurodegenerative diseases. The company has a nanotechnology drug platform for the development of orally administered neurotherapeutic drugs. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson’s; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company’s products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; and NM-PtAu7, a gold-platinum CSN therapeutic. Clene Inc. is based in Salt Lake City, Utah. |
Oklahoma City, Oklahoma, United States | COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now. | |
San Diego, California, United States | Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies. Our proprietary ENHEnS technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites. | |
Skokie, Illinois, United States | We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients. | |
Seattle, Washington, US | ||
919 Fraser Dr., Unit 11, Burlington, ON, L7L 4X8, Canada | Cytodiagnostics is a biotechnology and diagnostics company based in Burlington, ON, Canada, and Tulsa, OK, USA, and a Research and Development Position at the Innovate Calgary Life Science Hub at the University of Calgary. Over the past fifteen years, Cytodiagnostics has become the pre-eminent global supplier of gold and silver nanoparticles. With a commitment to providing quality materials, our in-depth knowledge of particle behaviour spans from initial synthesis to chemical functionalization and detection molecule conjugation, giving us a unique advantage for incorporating nanoparticles into diagnostic tests. This realization led to the creation of CytoGROUP, a branch of our business with the mission of using excellent materials to provide top-notch lab-based and point-of-care diagnostics. Our team has applied their expertise with chemical modifications as well as antibody and cutting-edge nucleic acid/aptamer detection molecules to create a range of products from lateral flow tests to plate-based assays, along with custom diagnostic test development services. In addition to our two locations, Cytodiagnostics also has an associate company, CytoGroup, which specializes in lateral flow and vertical flow assays, ELISA, ELASA and Aptamer Development. Both products and development services are available. Our goal is to serve our customers with the highest quality products to ensure success in their research and development efforts. | |
Turku, Finland | DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend and manage the life cycle of existing products. More patient-friendly products can be developed which release active compounds over days to many months. The technology is also well suited for challenging drug delivery needs such as controlled local delivery to the eye or the brain. At DelSiTech, we are also developing our own in-house supergeneric drug products for significant unmet medical and market needs. Our lead product, 1308, is a 3 month subcutaneous product for hepatitis B. 1308 will enter clinical studies in Q1 2017. | |
San Diego, California, United States | Direct Electron designs, manufactures, and delivers next-generation direct detection cameras for electron microscopy. Our vision—Innovation Propelling Discovery—is focused on empowering our customers to efficiently and continually expand the frontiers of science. Our approach involves: (1) A strong commitment to research and development that enables us to continually offer new technological innovations, (2) Unique features to improve efficiency in data collection and processing, and (3) A collaborative culture with exceptional customer service and support. | |
67 Abdelaziz Al Saud St., Manial, Cairo Governorate, EG, 11553 | D-Kimia develops nano-particle based diagnostic solutions to detect a broad range of diseases by targeting the nucleic acid signature of the disease. Our diagnostic solutions are rapid, affordable, simple to use, and provide the same level of specificity as the most advanced Polymerase Chain Reaction (PCR), and other amplification- based diagnostic techniques. The Hepatitis C Virus (HCV) infects over 170 million people worldwide and continues to spread across the globe. D-Kimia's patent pending platform has initially been optimized for the identification of the Hepatitis C virus. Our assay offers rapid, accurate, and affordable molecular detection of HCV without expensive and complicated lab equipment. D-Kimia is further developing its diagnostic platform to identify the nucleic acid signature of a range of viruses and genetic disease markers including tuberculosis, malaria, breast cancer and bladder cancer. | |
Indianola, Iowa, United States | DNP123 is a startup focused on solving nanotech manufacturing problems. We work with industry, government labs, and academic research groups to enable the design and assembly of novel nanotech devices. DNP123’s patent-pending core IP—DNA-patched nanocubes that self-assemble designable structures—affords a simple, standardized method of assembling almost any three-dimensional structure at nanoscale. | |
Columbia, South Carolina, United States | Doty Scientific, Inc. was founded by Dr. F. David Doty (president and chief engineering scientist) in May 1982, in Columbia, South Carolina, for the primary purpose of designing and manufacturing scientific instrumentation. The company’s initial product was a CP/MAS (Cross Polarization/Magic Angle Spinning) probe for chemical structure determination of solid materials via Nuclear Magnetic Resonance (NMR). | |
139A Charles St, Boston, Massachusetts, USA, 02114 | Based on DNA nanotechnology, our novel family of Janus base nanomaterials provides highly effective, super biocompatible solutions that enable enhanced therapeutic delivery and regenerative medicine for articular cartilage, central nervous system disorders, solid tumors, and other chronic conditions. Our three generations of DNA-inspired nanotubes are a cost-effective alternative to existing options, and they have excellent scalability. We can customize our Janus base nanotechnologies to enhance the therapeutic efficacy of drug treatments for a variety of chronic conditions and medical needs. | |
Warrendale, Pennsylvania | Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics' patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy. | |
Simpsonville, South Carolina, United States | Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting. | |
Paris, France | Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing. | |
57 Didsbury Street, East Brisbane, QLD 4169, AU | Ellume is an Australian based Health Technology company that develops and manufactures connected real-time diagnostics for doctors and consumers. We achieve this by combining next-generation quantum dot diagnostics with connected care technologies. Our products are distinguished by their simplicity of design, ease of use, rapid time to result and connectivity. To learn more about Ellume, visit our website at www.ellumehealth.com. | |
New York, New York, United States | Developing chemotherapies. | |
San Diego, California, United States | Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses. | |
10230 Jasper Avenue, Unit 4550, Edmonton, Alberta T5J 4P6, CA | Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion. | |
Ottawa, Ontario, Canada | Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications. | |
San Francisco, California, United States | Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP. | |
3805 Old Easton Rd, Doylestown, Pennsylvania 18902, US | Advancing the Science of exosomes and precision Growth Factors, Exocel Bio strives to be the leader in the regenerative aesthetic industry by leveraging our nanoparticle technology platform, and is dedicated to the pursuit of making anti-aging a reality. EXOVEX is a skin post Laser or Microneedling treatment packed with exosomes and precision growth factors that have been formulated to accelerate recovery and enhance efficacy by improving the appearance of hair, fine lines, wrinkles, skin tone and texture. | |
20 Fortune Drive, Billerica, MA 01821, US | Exogenesis Corporation is a privately-held, venture capital backed company developing and commercializing proprietary nanoscale surface modification and surface control technologies which have application in improving the safety and performance of implantable medical devices and improving the performance of optics, glass and a variety of substrates used in the laser, memory and semiconductor industries. Exogenesis NanoAccel technology has the unique ability to produce important atomic level surface modification effects without coatings or additives. The NanoAccel Gas Cluster Ion Beam (GCIB) technology was originally developed to provide nanoscale surface processing of semiconductors and other opto-electronic devices. Exogenesis acquired the exclusive worldwide rights to GCIB intellectual property for biomedical applications. Subsequently, Exogenesis developed a complementary particle beam technology - Accelerated Neutral Atom Beam. Exogenesis welcomes the opportunity to explore interest in commercializing the NanoAccel process. Additional information on NanoAccel technologies and their application can be found at www.exogenesis.us Contact Dmitry Shashkov, Exogenesis President and CEO, at dshashkov@exogenesis.us for more information. | |
Columbus, Ohio, United States | ExonanoRNA is a platform biotechnology company developing a new class of RNA nanotechnology-based therapeutics for cancer treatment. They provide the best work on RNA Nanotechnology, RNA DNA Oligos, and Exosome Research. | |
Surrey, British Columbia | At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs. | |
Olathe, Kansas, United States | The mission of Foothold Labs is to develop a next generation rapid diagnostic platform for point of care healthcare applications. Our NanoRev System uses artificial intelligence enabled electrochemical biosensors to rapidly detect infectious disease related biomarkers in saliva in five minutes for under $35 per test. We have partnerships with the Naval Research Laboratory, MIT Chemistry, and the University of Kansas Bioengineering program. Additionally, we have captured more than $1.5MM in SBIR grant funding from the US Air Force and US Special Operations Command over the last twelve months. (As of May 2022) | |
South San Francisco, California, United States | GenEdit is revolutionizing genetic medicines by developing innovative therapies through targeted delivery of genetic medicines. | |
Cambridge, Massachusetts, United States of America | Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts. | |
Lund, Sweden | Genovis offers a unique range of rapid and easy to use enzymatic tools primarily for the biopharmaceutical industry. Available worldwide, these SmartEnzymes™ are supplied in innovative formats for the development, production and quality control of biological drugs such as monoclonal antibodies, ADCs, biosimilars and bispecifics. The Genovis SmartEnzymes are widely used for the digestion, de-glycosylation and conjugation of the target molecule and are an ideal companion to popular analytical techniques like LC-MS. Within the portfolio there are enzymes specific for: IgG digestion - FabRICATOR™, FabALACTICA™, GingisKHAN™, FabULOUS™ & FabRICATOR Z™ General proteolysis - GingisREX™ De-glycosylation and conjugation of IgGs - GlycINATOR™, IgGZERO™ and GlyCLICK™ O-glycan analysis - OglyZOR™, OpeRATOR™, GlycOCATCH™ and SialEXO™ |